Literature DB >> 12528767

Regulation and targets of receptor tyrosine kinases.

Tony Pawson1.   

Abstract

Ligand-mediated activation of receptor tyrosine kinases (RTKs) results in autophosphorylation of both the receptor catalytic domain and noncatalytic regions of the cytoplasmic domain. Catalytic domain phosphorylation leads to activation and potentiation of receptor kinase activity. Noncatalytic domain phosphorylation creates docking sites for downstream cytoplasmic targets, which bind to specific receptor phosphotyrosine residues. Downstream signaling pathways are constructed in a modular fashion. In addition to SH2 and PTB (phosphotyrosine binding) domains, downstream signal proteins also contain domains that recognize other protein and phospholipid motifs. The arrangement and re-arrangement of various combinations of modular domains in different signaling proteins (combinatorial use) has allowed for the creation of complex signaling networks and pathways. In addition to performing catalytic functions, signaling proteins serve as scaffolds for the assembly of multiprotein signaling complexes, as adaptors, as transcription factors and as signal pathway regulators. Recent results show that the juxtamembrane region of Eph receptors is important in receptor autoregulation. Mutations in the juxtamembrane region of several RTKs have been shown to play a role in oncogenesis. It is likely that dysregulation of other modular components of signaling pathways also plays a role in oncogenic transformation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12528767     DOI: 10.1016/s0959-8049(02)80597-4

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  69 in total

1.  The expression of Akt and ERK1/2 proteins decreased in dexamethasone-induced intrauterine growth restricted rat placental development.

Authors:  Asli Ozmen; Gozde Unek; Dijle Kipmen-Korgun; Emin Turkay Korgun
Journal:  J Mol Histol       Date:  2011-04-23       Impact factor: 2.611

2.  The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.

Authors:  Dwight D Kloth; Lew Iacovelli; Rebecca Arbuckle; Angela C McIntosh
Journal:  P T       Date:  2010-04

3.  Screening for PTB domain binding partners and ligand specificity using proteome-derived NPXY peptide arrays.

Authors:  Matthew J Smith; W Rod Hardy; James M Murphy; Nina Jones; Tony Pawson
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

Review 4.  Ras nanoclusters: combining digital and analog signaling.

Authors:  Angus Harding; John F Hancock
Journal:  Cell Cycle       Date:  2007-10-26       Impact factor: 4.534

Review 5.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Authors:  Marina Konopleva; Yoko Tabe; Zhihong Zeng; Michael Andreeff
Journal:  Drug Resist Updat       Date:  2009-07-25       Impact factor: 18.500

Review 6.  NGF and ProNGF: Regulation of neuronal and neoplastic responses through receptor signaling.

Authors:  Ralph A Bradshaw; Jay Pundavela; Jordane Biarc; Robert J Chalkley; A L Burlingame; Hubert Hondermarck
Journal:  Adv Biol Regul       Date:  2014-11-20

7.  Deciphering Phosphotyrosine-Dependent Signaling Networks in Cancer by SH2 Profiling.

Authors:  Kazuya Machida; Malik Khenkhar; Peter Nollau
Journal:  Genes Cancer       Date:  2012-05

Review 8.  Kinase mutations in human disease: interpreting genotype-phenotype relationships.

Authors:  Piya Lahiry; Ali Torkamani; Nicholas J Schork; Robert A Hegele
Journal:  Nat Rev Genet       Date:  2010-01       Impact factor: 53.242

9.  Dissecting the roles of tyrosines 490 and 785 of TrkA protein in the induction of downstream protein phosphorylation using chimeric receptors.

Authors:  Jordane Biarc; Robert J Chalkley; A L Burlingame; Ralph A Bradshaw
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

10.  Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.

Authors:  Catia Cemeus; Tong T Zhao; Gordon M Barrett; Ian A Lorimer; Jim Dimitroulakos
Journal:  J Neurooncol       Date:  2008-06-20       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.